Sutro Biopharma
A clinical-stage biotechnology company developing cancer medicines through cell-free protein synthesis, protein engineering, and site-specific antibody-drug conjugate technology.
Last updated August 24, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 3
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Sutro Biopharma is a public biotechnology company headquartered in South San Francisco, California. The company works on the discovery, development, and manufacturing of protein-based medicines, with an emphasis on oncology. Its research is built around a proprietary cell-free protein synthesis platform derived from Open Cell-Free Synthesis technology developed from work associated with Stanford University professor James R. Swartz. Sutro applies this platform to the design and rapid production of antibodies, cytokines, bispecific proteins, and antibody-drug conjugates (ADCs). The company was established in 2003 under the name Fundamental Applied Biology and adopted the Sutro Biopharma name in 2009. Its technology platform, known as XpressCF and later XpressCF+, is intended to accelerate the expression and screening of many protein variants in parallel. XpressCF+ also supports the incorporation of non-natural amino acids at defined locations in a protein. Sutro uses that capability to produce more uniform, site-specific ADCs, in which a therapeutic payload is attached to an antibody at controlled positions rather than through a less homogeneous process. Sutro's development strategy has concentrated on clinically validated biological targets where existing treatment options may be inadequate. Its programs have included ADCs, cytokine-based immuno-oncology therapies, and bispecific antibodies. STRO-001 is an ADC directed at CD74, a target expressed in diseases including multiple myeloma and non-Hodgkin lymphoma. STRO-002, subsequently known as luveltamab tazevibulin or luvelta, is an ADC directed at folate receptor alpha, a target associated with several gynecological cancers. These assets have represented important elements of Sutro's internally developed oncology pipeline, although development status and clinical outcomes can change as trials progress. Sutro has also used partnerships to expand the application of its platform. In 2014 it entered an immuno-oncology collaboration with Celgene; the parties later refocused that relationship on four preclinical programs, including an ADC program directed at B-cell maturation antigen. In 2018 Sutro announced a collaboration and licensing agreement with Merck to discover and develop cytokine-based therapies for cancer and autoimmune disorders. The agreement included a reported upfront payment of $60 million and potential development and commercial milestone payments of up to $1.6 billion across applicable candidates and indications, subject to the terms of the agreement. The company operates a current-good-manufacturing-practice facility in San Carlos, California, giving it an internal capability to scale production of selected protein drug candidates. Its technology also contributed to the creation of SutroVax, a vaccine-focused spin-off founded in 2015. Sutro became a publicly traded company on the Nasdaq in 2018 under the ticker STRO. As of the cited 2024 reference material, William Newell served as chief executive officer, having joined the company in January 2009. Sutro's market identity is that of a research-driven oncology biotechnology company seeking to combine biologic design, controlled conjugation chemistry, and flexible manufacturing rather than compete as a broad commercial pharmaceutical portfolio.
History
Sutro Biopharma began in 2003 under the name Fundamental Applied Biology. The company was created to commercialize and apply cell-free protein synthesis methods for the discovery and production of engineered proteins. In 2009 it adopted the Sutro Biopharma name, aligning the corporate identity with its focus on biologic drug discovery and development. William Newell joined the company in January 2009 and was identified as chief executive officer in the cited 2024 material. The foundation of Sutro's technology is Open Cell-Free Synthesis, an approach associated with patented work by Stanford professor James R. Swartz. Unlike conventional methods that rely on living cells to manufacture proteins, cell-free systems use biological machinery outside intact cells. Sutro developed this concept into its XpressCF platform, which is designed to express and evaluate many protein variants in parallel, potentially shortening early discovery cycles. The platform can be applied to several protein classes, including antibodies, cytokines, vaccine carrier proteins, and other antibody-based constructs. Sutro subsequently developed XpressCF+, adding the ability to place non-natural amino acids at selected points in a protein sequence. This capability became particularly relevant to antibody-drug conjugates. By controlling the attachment sites for drug payloads, the company aims to make ADC products with greater structural consistency than products created through less selective conjugation methods. Sutro combines discovery capabilities with a cGMP manufacturing facility in San Carlos, California, allowing selected candidates to be advanced toward clinical production and scale-up within the company's own operating network. The company's first major therapeutic focus has been oncology. Its internally developed ADC programs have included STRO-001, which targets CD74, a protein expressed in multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which targets folate receptor alpha and has been known as luveltamab tazevibulin or luvelta. Sutro has also investigated cytokine-based immuno-oncology therapies and bispecific antibodies, generally emphasizing targets with established clinical relevance but treatment gaps. Sutro expanded its external relationships during the 2010s. It entered an immuno-oncology collaboration with Celgene in 2014. By 2017, the companies had refocused that collaboration on four preclinical programs, including a B-cell maturation antigen ADC program. In 2015, technology associated with Sutro contributed to the formation of SutroVax, a vaccine-focused spin-off that subsequently raised substantial private capital according to the cited reference material. In July 2018, Sutro announced a collaboration and licensing agreement with Merck covering cytokine-based therapies for cancer and autoimmune diseases. The arrangement included a $60 million upfront payment and potential milestone payments of up to $1.6 billion across the relevant development and commercial opportunities, subject to contractual conditions. The agreement demonstrated how Sutro sought to monetize its discovery platform through partnerships while retaining internal oncology programs. Sutro became a public company on Nasdaq in 2018 under the symbol STRO. Around the same period, its XpressCF platform received recognition at the World ADC event as Best ADC Technology Platform, and Sutro was listed among Fierce Biotech's Fierce 15 in 2014. The company also received the DiNA Outstanding Partner Award from the California Life Sciences Association in 2015. As described in the 2024 reference material, Sutro remained a clinical-stage biotechnology company focused on advancing ADCs, cytokine therapies, and bispecific antibodies rather than marketing a broad portfolio of approved medicines.
- 2018
Nasdaq listing
[1]Sutro became publicly traded on Nasdaq under the ticker STRO.
- 2018
Merck collaboration announced
[1]Sutro entered a cytokine-focused discovery and development collaboration with Merck covering cancer and autoimmune indications.
- 2017
Celgene collaboration refocused
[1]The Celgene relationship was refocused on four preclinical programs, including an ADC program directed at B-cell maturation antigen.
- 2015
SutroVax spin-off formed
[1]Technology associated with Sutro contributed to the creation of SutroVax, a vaccine-focused biotechnology spin-off.
- 2015
DiNA Outstanding Partner Award
[1]Sutro received the DiNA Outstanding Partner Award from the California Life Sciences Association.
- 2014
Celgene immuno-oncology collaboration begins
[1]Sutro and Celgene entered an immuno-oncology collaboration involving the discovery and development of protein-based cancer therapies.
- 2009
Company adopts the Sutro Biopharma name
[1]Fundamental Applied Biology changed its corporate name to Sutro Biopharma. William Newell joined the company in January of that year.
- 2003
Company founded as Fundamental Applied Biology
[1]The biotechnology company was established under the name Fundamental Applied Biology to develop applications of cell-free protein synthesis.
Products and positioning
An oncology-focused biotechnology innovator using cell-free protein synthesis, rational protein design, and site-specific conjugation to create differentiated biologic medicines and ADCs.
Antibody-drug conjugate
Luveltamab tazevibulin (luvelta; STRO-002)
Luveltamab tazevibulin, previously identified as STRO-002, is an antibody-drug conjugate directed at folate receptor alpha. This cell-surface target is highly expressed in several gynecological cancers. The program is one of Sutro's principal internally developed oncology assets and illustrates the company's use of site-specific conjugation and engineered antibody design.
Antibody-drug conjugate
STRO-001
STRO-001 is an antibody-drug conjugate targeting CD74, a protein expressed in multiple myeloma and non-Hodgkin lymphoma. The program was developed using Sutro's cell-free protein synthesis and conjugation capabilities and was described in the cited reference material as being evaluated in an early-stage clinical trial.
Biotechnology platform
XpressCF platform
XpressCF is Sutro's cell-free protein synthesis platform. It is designed to express and screen hundreds of protein variants in parallel, supporting discovery work across antibodies, cytokines, vaccine carrier proteins, and other engineered proteins. The platform is intended to reduce the time required for early protein design and evaluation.
ADC discovery and manufacturing technology
XpressCF+ platform
XpressCF+ extends the cell-free synthesis approach by enabling the controlled incorporation of non-natural amino acids into protein sequences. Sutro uses this capability to attach drug payloads at defined sites on antibodies, supporting more homogeneous ADC candidates and facilitating rational protein engineering.
Brand decisions
2018
Merck cytokine collaboration and licensing agreementM&ABackground
Sutro sought to apply its protein-engineering and cell-free synthesis capabilities beyond ADCs to cytokine-based immuno-oncology therapies.
Action taken
Sutro granted Merck collaboration and licensing rights for the discovery and development of cytokine-based therapies for cancer and autoimmune disorders.
Aftermath
The agreement provided a reported $60 million upfront payment and eligibility for potential milestone payments of up to $1.6 billion across relevant candidates and indications.
Potential collaboration milestone payments. Up to $1.6 billion (Announced July 2018; contingent on development and commercial milestones)
2018
Public-market listingOtherBackground
Sutro was a clinical-stage biotechnology company seeking public capital to support therapeutic development.
Action taken
The company listed its shares on Nasdaq under the ticker STRO.
Aftermath
Sutro became a publicly traded biotechnology company while continuing to advance its oncology pipeline.
2017
Refocus of Celgene collaborationStrategyBackground
Sutro and Celgene had maintained an immuno-oncology collaboration since 2014.
Action taken
The partners concentrated the relationship on four preclinical programs, including an ADC directed at B-cell maturation antigen.
Aftermath
The refocusing aligned the collaboration more closely with selected oncology programs and clinically relevant targets.
2009
Rebrand as Sutro BiopharmaStrategyBackground
The company had been operating under the name Fundamental Applied Biology since its 2003 formation.
Action taken
It changed its corporate name to Sutro Biopharma, establishing the identity used for its subsequent biotechnology and oncology activities.
Aftermath
The renamed company continued developing cell-free protein synthesis applications and protein-based therapeutics.
Recent events
Reported
Sutro Biopharma prices $126 million public offering[3]
Sutro Biopharma announced the pricing of an underwritten public offering of 6 million common shares at $21 per share. The offering was expected to close on or about December 11, subject to customary closing conditions.
Reported
Sutro Biopharma promotes two executives to vice president roles[4]
Sutro Biopharma announced the promotions of Carlos Lugo to Vice President of Quality and CMC Regulatory Operations and Devendra Luhar to Vice President of Manufacturing & Plant Operations.
Reported
Sutro Biopharma appoints James Panek to its board[5]
Sutro Biopharma announced the appointment of James P. Panek to its Board of Directors on January 8, 2020.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sutro-biopharma · Editorial policy · How profiles are compiled